An oral research peptide is a short-chain amino acid sequence — typically 2 to 40 residues — formulated into a capsule or tablet intended for administration via the gastrointestinal route in preclinical study subjects. The term “research peptide” specifically denotes that the compound is supplied for laboratory investigation, not for therapeutic or diagnostic use in humans.

Peptides in this category are structurally identical to their injectable counterparts but require additional formulation steps — most critically enteric coating — to survive gastric transit. Once past the stomach, the active compound is released into the intestinal lumen where partial absorption through mucosal transport mechanisms can occur. The study of this process is itself an active area of oral vs. injectable peptide bioavailability research.

The principal difference is route of administration and resulting pharmacokinetic profile. Injectable peptides — subcutaneous, intravenous, or intramuscular — bypass gastrointestinal barriers entirely and typically achieve higher peak plasma concentrations with faster onset. Oral peptides must navigate gastric acid (pH 1.5–3.5), pancreatic proteases, and brush-border peptidases before any systemic absorption can occur.

In preclinical models, injectable peptides generally yield more predictable dose-response curves. Oral formulations trade some of that precision for ease of administration in longer-duration studies and reduced stress on the research subject. Enteric-coated capsules represent the current gold standard for oral delivery of protease-sensitive peptides. See our full breakdown in our oral capsule delivery explainer.

Enteric coating is a polymer film — typically based on cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate (HPMCP), or methacrylic acid copolymers such as Eudragit L100 — applied to the outside of a capsule. This coating is stable at the low pH of stomach acid (approximately pH 1.5 to 3.5) but dissolves rapidly when pH rises above 5.5 to 6.0, which occurs in the proximal small intestine.

The practical effect: a peptide inside an enteric-coated capsule is shielded from gastric proteolysis for the 1–3 hours it spends in the stomach. Once the capsule enters the duodenum, the coating dissolves and the peptide is released into an environment with far more favorable absorptive potential. Without enteric coating, most peptides above 3–4 residues are substantially degraded by pepsin before reaching the intestine. This is why enteric-coated capsules are the delivery format of choice in current oral peptide preclinical work.

Research-use-only (RUO) compounds are chemical or biological materials manufactured and supplied specifically for laboratory investigation. They have not undergone the clinical trial process required by the FDA, EMA, or equivalent regulatory bodies for approval as drugs, and they carry no therapeutic claims. RUO labeling — often expressed as “not for human use” or “for research use only” — is a regulatory designation, not merely a disclaimer.

Clinical compounds, by contrast, are approved pharmaceutical products that have passed Phase I through Phase III (or Phase IV post-market) trials demonstrating safety and efficacy profiles sufficient for regulatory approval. The manufacturing standards also differ: RUO peptides are produced under research-grade GMP or ISO-certified conditions, whereas pharmaceutical-grade compounds must meet additional documentation, sterility, and traceability standards. Researchers sourcing RUO peptides are expected to handle them under appropriate institutional protocols.

Research grade typically connotes a defined minimum purity threshold — commonly 98%+ or 99%+ by HPLC — along with documentation of identity via mass spectrometry, residual solvent testing, and for peptides intended for in vivo work, endotoxin (LAL) testing. A genuine research-grade supplier provides a certificate of analysis (COA) from an independent third-party laboratory for every batch.

At Biohacker, all compounds are tested at 99%+ purity by HPLC and confirmed by MS. Endotoxin levels are tested using the Limulus Amebocyte Lysate (LAL) assay. COAs are batch-specific and publicly accessible on our COA verification page. Understanding how to read and verify these documents is a core skill for any serious researcher — see our guide to reading peptide COAs for a step-by-step walkthrough.

BPC-157 (Body Protective Compound-157) is a synthetic 15-amino acid peptide derived from a partial sequence of human gastric juice protein BPC. Its sequence is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The compound was isolated and characterized by Sikirić and colleagues in the 1990s and has since accumulated an extensive preclinical literature across multiple organ systems.

Preclinical interest centers on BPC-157’s apparent pleiotropic activity — observed effects span gastrointestinal mucosal integrity, tendon and ligament healing models, angiogenesis, and NO-system modulation. Its documented stability in gastric acid and activity following oral administration in rodent models makes it a particularly interesting subject for oral delivery research. A comprehensive overview is available at our BPC-157 research benefits article.

Several factors converge to make BPC-157 the reference compound in oral peptide research. First, it is endogenously derived — as a fragment of a protein found in human gastric juice, it has demonstrated resistance to acidic and enzymatic degradation that most exogenous peptides lack. This inherent acid-stability gave early researchers confidence that oral administration could produce measurable systemic or local effects in animal models.

Second, its research history is unusually deep for an RUO compound. Sikirić’s group and subsequent independent teams have produced hundreds of peer-reviewed studies across rat, mouse, and rabbit models covering gastrointestinal, musculoskeletal, cardiovascular, and neurological endpoints. This body of evidence gives researchers a well-characterized reference point for dosing, timing, and outcome measurement. Third, oral BPC-157 is technically simpler to administer in longer-duration studies, reducing confounders introduced by repeated injection stress. Our BPC-157 capsules page includes current batch availability and COA links.

Head-to-head route-comparison data in the BPC-157 literature is instructive. Multiple studies from Sikirić’s laboratory and corroborating groups have demonstrated that oral (intragastric) and injectable (intraperitoneal or subcutaneous) administration of BPC-157 at comparable dose ranges produced similar outcomes in wound healing and GI protection models in rats. The effect magnitude was generally comparable across routes, though onset kinetics and bioavailability profiles differ.

This is mechanistically interesting because most peptides of similar length would be expected to degrade substantially in the GI environment. BPC-157’s apparent oral activity is hypothesized to result from a combination of local mucosal action (particularly relevant for GI endpoint studies) and partial systemic absorption. Researchers designing protocols should note that route selection affects both the primary endpoint under investigation and the dose titration strategy. The BPC-157 vs. TB-500 comparison article covers route and application differences in more detail.

In tendon and ligament healing models, researchers typically quantify histological outcomes (collagen fiber organization, fibroblast density, vascularization), biomechanical parameters (tensile strength, load-to-failure), and inflammatory marker expression (IL-6, TNF-α, TGF-β1) at defined post-injury timepoints. Rodent models most commonly used include partial Achilles tendon transection in rats and surgically induced medial collateral ligament tears.